Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 15 Researches
7.4
USERS' SCORE
Good
Based on 7 Reviews
8.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
15
Total Fat
1.5 g
2%**
Wild Caught Fish Oil Concentrate
1250 mg
†
Total Omega-3 Fatty Acids as TG
1055 mg
†
EPA (Eicosapentaenoic Acid)
690 mg
†
DHA (Docosahexaenoic Acid)
310 mg
†
Other Omega-3 Fatty Acids
55 mg
†
Top Medical Research Studies
9.5
We conducted a thorough investigation into how eicosapentaenoic acid (EPA) can impact episodic migraines. In a carefully designed study, we gathered 70 participants who experienced these migraines and divided them into two groups. One group received a high dose of EPA, while the other was given a placebo. This approach ensured that we could see the true effects of EPA without bias.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
Read More
9
We explored the effectiveness of high-dose omega-3 fatty acids, specifically EPA and DHA, in preventing migraines. Analyzing 40 clinical trials, we found that supplementation significantly reduced both the frequency and severity of migraine attacks compared to a placebo.
Not only did these omega-3s outperform other treatments, but they also showed good acceptability, meaning fewer people dropped out due to side effects. Overall, this suggests that high dosage EPA/DHA could be a strong option for those seeking relief from migraines.
Not only did these omega-3s outperform other treatments, but they also showed good acceptability, meaning fewer people dropped out due to side effects. Overall, this suggests that high dosage EPA/DHA could be a strong option for those seeking relief from migraines.
Read More
9
We investigated how the intake of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, might affect the frequency of migraine attacks. In a study involving 105 migraine patients aged 15 to 50, we examined their usual dietary habits through a food frequency questionnaire and tracked their migraine occurrences over a month.
Our findings revealed a notable trend: lower consumption of EPA was tied to an increased number of migraine attacks. Specifically, participants with reduced EPA intake experienced a higher frequency of migraines, with data indicating a significant statistical relationship. We also found that this connection held true for both men and women alike, emphasizing the potential importance of dietary choices in managing migraines.
Conversely, we did not observe any significant link between saturated fatty acids (SFA) and migraine frequency, suggesting that not all dietary fats impact migraines the same way. Overall, our results point to a promising association between omega-3 fatty acids, particularly EPA, and reduced migraine attacks, inviting further research to deepen our understanding of this relationship.
Our findings revealed a notable trend: lower consumption of EPA was tied to an increased number of migraine attacks. Specifically, participants with reduced EPA intake experienced a higher frequency of migraines, with data indicating a significant statistical relationship. We also found that this connection held true for both men and women alike, emphasizing the potential importance of dietary choices in managing migraines.
Conversely, we did not observe any significant link between saturated fatty acids (SFA) and migraine frequency, suggesting that not all dietary fats impact migraines the same way. Overall, our results point to a promising association between omega-3 fatty acids, particularly EPA, and reduced migraine attacks, inviting further research to deepen our understanding of this relationship.
Read More
Most Useful Reviews
10
Migraine relief
What a quality omega! The effect is highly noticeable, particularly on my skin. My migraine has disappeared.
Read More
10
Migraine aid
I really love this fish oil; it has helped me get rid of my migraines.
Read More
7.5
Less migraines
I ordered this omega due to its high concentration and DHA/EPA ratio. It helped me restore my strength and nervous system after COVID-19 during a time of severe tension. My migraines have decreased, and I feel more physically fit.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 15 Researches
7.4
- All Researches
9.5
We conducted a thorough investigation into how eicosapentaenoic acid (EPA) can impact episodic migraines. In a carefully designed study, we gathered 70 participants who experienced these migraines and divided them into two groups. One group received a high dose of EPA, while the other was given a placebo. This approach ensured that we could see the true effects of EPA without bias.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
Read More
9
We explored the effectiveness of high-dose omega-3 fatty acids, specifically EPA and DHA, in preventing migraines. Analyzing 40 clinical trials, we found that supplementation significantly reduced both the frequency and severity of migraine attacks compared to a placebo.
Not only did these omega-3s outperform other treatments, but they also showed good acceptability, meaning fewer people dropped out due to side effects. Overall, this suggests that high dosage EPA/DHA could be a strong option for those seeking relief from migraines.
Not only did these omega-3s outperform other treatments, but they also showed good acceptability, meaning fewer people dropped out due to side effects. Overall, this suggests that high dosage EPA/DHA could be a strong option for those seeking relief from migraines.
Read More
9
We investigated how the intake of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, might affect the frequency of migraine attacks. In a study involving 105 migraine patients aged 15 to 50, we examined their usual dietary habits through a food frequency questionnaire and tracked their migraine occurrences over a month.
Our findings revealed a notable trend: lower consumption of EPA was tied to an increased number of migraine attacks. Specifically, participants with reduced EPA intake experienced a higher frequency of migraines, with data indicating a significant statistical relationship. We also found that this connection held true for both men and women alike, emphasizing the potential importance of dietary choices in managing migraines.
Conversely, we did not observe any significant link between saturated fatty acids (SFA) and migraine frequency, suggesting that not all dietary fats impact migraines the same way. Overall, our results point to a promising association between omega-3 fatty acids, particularly EPA, and reduced migraine attacks, inviting further research to deepen our understanding of this relationship.
Our findings revealed a notable trend: lower consumption of EPA was tied to an increased number of migraine attacks. Specifically, participants with reduced EPA intake experienced a higher frequency of migraines, with data indicating a significant statistical relationship. We also found that this connection held true for both men and women alike, emphasizing the potential importance of dietary choices in managing migraines.
Conversely, we did not observe any significant link between saturated fatty acids (SFA) and migraine frequency, suggesting that not all dietary fats impact migraines the same way. Overall, our results point to a promising association between omega-3 fatty acids, particularly EPA, and reduced migraine attacks, inviting further research to deepen our understanding of this relationship.
Read More
9
We conducted a randomized trial to understand how modifying dietary omega-3 and omega-6 fatty acids influences chronic headache conditions, particularly migraines. Patients with daily headaches followed two different dietary plans: one that included a high level of omega-3 and a low level of omega-6, and another that just reduced omega-6 intake. Over 12 weeks, we gathered both clinical and biochemical data to evaluate the outcomes.
Interestingly, the results highlighted that the group consuming more omega-3 fatty acids had significant improvements in their headache symptoms. They reported fewer headache days per month and spent less time each day suffering from headaches compared to those who only lowered their omega-6 intake. Additionally, we noted notable changes at the biochemical level, indicating increased levels of certain markers related to pain relief in the higher omega-3 group.
Our findings suggest that enhancing omega-3 intake while reducing omega-6 can lead to better management of chronic headaches, altering pain-related lipid mediators and ultimately improving quality of life for those suffering from such conditions.
Interestingly, the results highlighted that the group consuming more omega-3 fatty acids had significant improvements in their headache symptoms. They reported fewer headache days per month and spent less time each day suffering from headaches compared to those who only lowered their omega-6 intake. Additionally, we noted notable changes at the biochemical level, indicating increased levels of certain markers related to pain relief in the higher omega-3 group.
Our findings suggest that enhancing omega-3 intake while reducing omega-6 can lead to better management of chronic headaches, altering pain-related lipid mediators and ultimately improving quality of life for those suffering from such conditions.
Read More
8
In a recent study aimed at understanding the role of eicosapentaenoic acid (EPA) in treating chronic migraines, we conducted a random, placebo-controlled trial with participants diagnosed with chronic migraines. The participants were split into two groups; one group received 1000 mg of EPA twice daily for eight weeks, while the other group took placebo softgels.
Our main focus was to evaluate whether daily EPA supplementation could reduce the frequency of migraine attacks and improve overall quality of life. We carefully tracked symptoms at four and eight weeks, relying on established measures like the Headache Impact Test-6 to quantify changes.
The results from this study were promising. We observed that taking 2000 mg of EPA daily showed potential benefits as a preventative treatment for chronic migraines. Participants reported a decrease in migraine headache days and lower severity levels, making it a valuable option to consider in managing chronic migraines effectively.
Our main focus was to evaluate whether daily EPA supplementation could reduce the frequency of migraine attacks and improve overall quality of life. We carefully tracked symptoms at four and eight weeks, relying on established measures like the Headache Impact Test-6 to quantify changes.
The results from this study were promising. We observed that taking 2000 mg of EPA daily showed potential benefits as a preventative treatment for chronic migraines. Participants reported a decrease in migraine headache days and lower severity levels, making it a valuable option to consider in managing chronic migraines effectively.
Read More
User Reviews
USERS' SCORE
Good
Based on 7 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
10
Migraine relief
What a quality omega! The effect is highly noticeable, particularly on my skin. My migraine has disappeared.
Read More
10
Migraine aid
I really love this fish oil; it has helped me get rid of my migraines.
Read More
7.5
Less migraines
I ordered this omega due to its high concentration and DHA/EPA ratio. It helped me restore my strength and nervous system after COVID-19 during a time of severe tension. My migraines have decreased, and I feel more physically fit.
Read More
9
Satisfactory results
I recently bought this omega for fitness, but I experienced different results. Since childhood, I've suffered from frequent headaches, but my migraines have nearly vanished; I haven't been ill for 15 days, which is a first. There were high cholesterol levels in recent tests, but I'm unsure if it's linked to the omega. Overall, I'm satisfied and would recommend it.
Read More
9
Reduced attacks
The effect is truly remarkable! I have heart valve issues, and this is my third purchase of this fish oil. Since taking it, my heart palpitations have lessened, and my memory has improved. Importantly, my long-term migraines have improved, and the frequency of my attacks has significantly decreased. I'm really grateful for this fish oil.
Read More
Frequently Asked Questions
9
Satisfactory results
I recently bought this omega for fitness, but I experienced different results. Since childhood, I've suffered from frequent headaches, but my migraines have nearly vanished; I haven't been ill for 15 days, which is a first. There were high cholesterol levels in recent tests, but I'm unsure if it's linked to the omega. Overall, I'm satisfied and would recommend it.
9
Reduced attacks
The effect is truly remarkable! I have heart valve issues, and this is my third purchase of this fish oil. Since taking it, my heart palpitations have lessened, and my memory has improved. Importantly, my long-term migraines have improved, and the frequency of my attacks has significantly decreased. I'm really grateful for this fish oil.
10
Migraine relief
What a quality omega! The effect is highly noticeable, particularly on my skin. My migraine has disappeared.
10
Migraine aid
I really love this fish oil; it has helped me get rid of my migraines.
7.5
Less migraines
I ordered this omega due to its high concentration and DHA/EPA ratio. It helped me restore my strength and nervous system after COVID-19 during a time of severe tension. My migraines have decreased, and I feel more physically fit.
8
In a recent study aimed at understanding the role of eicosapentaenoic acid (EPA) in treating chronic migraines, we conducted a random, placebo-controlled trial with participants diagnosed with chronic migraines. The participants were split into two groups; one group received 1000 mg of EPA twice daily for eight weeks, while the other group took placebo softgels.
Our main focus was to evaluate whether daily EPA supplementation could reduce the frequency of migraine attacks and improve overall quality of life. We carefully tracked symptoms at four and eight weeks, relying on established measures like the Headache Impact Test-6 to quantify changes.
The results from this study were promising. We observed that taking 2000 mg of EPA daily showed potential benefits as a preventative treatment for chronic migraines. Participants reported a decrease in migraine headache days and lower severity levels, making it a valuable option to consider in managing chronic migraines effectively.
Our main focus was to evaluate whether daily EPA supplementation could reduce the frequency of migraine attacks and improve overall quality of life. We carefully tracked symptoms at four and eight weeks, relying on established measures like the Headache Impact Test-6 to quantify changes.
The results from this study were promising. We observed that taking 2000 mg of EPA daily showed potential benefits as a preventative treatment for chronic migraines. Participants reported a decrease in migraine headache days and lower severity levels, making it a valuable option to consider in managing chronic migraines effectively.
9.5
We conducted a thorough investigation into how eicosapentaenoic acid (EPA) can impact episodic migraines. In a carefully designed study, we gathered 70 participants who experienced these migraines and divided them into two groups. One group received a high dose of EPA, while the other was given a placebo. This approach ensured that we could see the true effects of EPA without bias.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
7
Eicosapentaenoic acid reduces migraine duration
We conducted a systematic review to understand how eicosapentaenoic acid (a type of omega-3 fatty acid) affects migraine headaches. By comparing data from various randomized controlled trials, we aimed to shed light on how this supplement might influence the frequency, severity, and duration of migraines.
Out of the thirteen studies we examined, we found that eicosapentaenoic acid did not significantly alter the frequency or severity of migraine attacks. This means that while it may not help reduce the number of migraines or their intensity, it did show promising results in terms of shortening their duration.
Specifically, we noted a significant reduction in migraine duration by about 3.44 hours with omega-3 intake. Our analysis suggests that while eicosapentaenoic acid may not be a game-changer for every aspect of migraines, it can help make them shorter when they do occur.
In conclusion, further research with high-quality trials and larger sample sizes is necessary to confirm these findings and explore more about the role of eicosapentaenoic acid in migraine management.
Out of the thirteen studies we examined, we found that eicosapentaenoic acid did not significantly alter the frequency or severity of migraine attacks. This means that while it may not help reduce the number of migraines or their intensity, it did show promising results in terms of shortening their duration.
Specifically, we noted a significant reduction in migraine duration by about 3.44 hours with omega-3 intake. Our analysis suggests that while eicosapentaenoic acid may not be a game-changer for every aspect of migraines, it can help make them shorter when they do occur.
In conclusion, further research with high-quality trials and larger sample sizes is necessary to confirm these findings and explore more about the role of eicosapentaenoic acid in migraine management.
5
In a recent study, we explored the effectiveness of eicosapentaenoic acid (EPA), a type of omega-3 polyunsaturated fatty acid, in preventing migraines. The study involved a structured approach where patients went through a 4-week single-blind placebo run-in period. After that, they were randomly assigned to receive either EPA at a dosage of 6 grams daily or a placebo for 16 weeks, followed by a 4-week run-out period.
We found that while the overall number of migraine attacks during the treatment period showed a slight difference, it wasn't statistically significant. Patients taking EPA experienced around 5.95 attacks on average over four months, whereas those on placebo had about 7.05 attacks. However, when looking at the last month of treatment only, there was no major difference, with those on EPA reporting 1.20 attacks compared to 1.26 in the placebo group.
Interestingly, patients in both groups showed a marked reduction in attacks from the initial run-in phase, highlighting a strong placebo effect. Despite some mild side effects related to gastrointestinal issues, most participants tolerated the EPA well. Overall, this large-scale study did not align with previous smaller studies that suggested a significant benefit from EPA for migraines, ultimately indicating no meaningful advantage of using eicosapentaenoic acid for migraine prevention.
We found that while the overall number of migraine attacks during the treatment period showed a slight difference, it wasn't statistically significant. Patients taking EPA experienced around 5.95 attacks on average over four months, whereas those on placebo had about 7.05 attacks. However, when looking at the last month of treatment only, there was no major difference, with those on EPA reporting 1.20 attacks compared to 1.26 in the placebo group.
Interestingly, patients in both groups showed a marked reduction in attacks from the initial run-in phase, highlighting a strong placebo effect. Despite some mild side effects related to gastrointestinal issues, most participants tolerated the EPA well. Overall, this large-scale study did not align with previous smaller studies that suggested a significant benefit from EPA for migraines, ultimately indicating no meaningful advantage of using eicosapentaenoic acid for migraine prevention.
9
We explored the effectiveness of high-dose omega-3 fatty acids, specifically EPA and DHA, in preventing migraines. Analyzing 40 clinical trials, we found that supplementation significantly reduced both the frequency and severity of migraine attacks compared to a placebo.
Not only did these omega-3s outperform other treatments, but they also showed good acceptability, meaning fewer people dropped out due to side effects. Overall, this suggests that high dosage EPA/DHA could be a strong option for those seeking relief from migraines.
Not only did these omega-3s outperform other treatments, but they also showed good acceptability, meaning fewer people dropped out due to side effects. Overall, this suggests that high dosage EPA/DHA could be a strong option for those seeking relief from migraines.
8
Eicosapentaenoic acid ineffective for migraines
We explored the effects of eicosapentaenoic acid on episodic migraine through a 12-week randomized double-blind clinical trial. This type of study is designed to rigorously assess the effectiveness of treatments by ensuring that neither the participants nor the researchers know who is receiving the actual treatment or a placebo.
Our goal was to see whether this omega-3 fatty acid could provide relief for those suffering from migraines. We observed how participants responded and measured the frequency and severity of their migraine attacks. Unfortunately, the results did not show a significant benefit of eicosapentaenoic acid in reducing migraine occurrences or intensity.
It is essential for those looking for migraine treatments to be aware that while eicosapentaenoic acid has been noted for various health benefits, our study concluded it does not effectively alleviate episodic migraines. Therefore, it may not be a viable option for migraine relief.
Our goal was to see whether this omega-3 fatty acid could provide relief for those suffering from migraines. We observed how participants responded and measured the frequency and severity of their migraine attacks. Unfortunately, the results did not show a significant benefit of eicosapentaenoic acid in reducing migraine occurrences or intensity.
It is essential for those looking for migraine treatments to be aware that while eicosapentaenoic acid has been noted for various health benefits, our study concluded it does not effectively alleviate episodic migraines. Therefore, it may not be a viable option for migraine relief.
References
- Tseng PT, Zeng BY, Chen JJ, Kuo CH, Zeng BS, et al. High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis. Adv Nutr. 2024;15:100163. doi:10.1016/j.advnut.2023.100163
- Mohammadnezhad G, Assarzadegan F, Koosha M, Esmaily H. Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial. Headache. 2025;65:153. doi:10.1111/head.14808
- You ZB, Cao P. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain Behav Immun. 2024;121:121. doi:10.1016/j.bbi.2024.07.014
- Chen TB, Yang CC, Tsai IJ, Yang HW, Hsu YC, et al. Neuroimmunological effects of omega-3 fatty acids on migraine: a review. Front Neurol. 2024;15:1366372. doi:10.3389/fneur.2024.1366372
- Wang HF, Liu WC, Zailani H, Yang CC, Chen TB, et al. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain Behav Immun. 2024;118:459. doi:10.1016/j.bbi.2024.03.019
- Faurot KR, Cole WR, MacIntosh BA, Dunlap M, Moore CB, et al. Targeted dietary interventions to reduce pain in persistent post-traumatic headache among service members: Protocol for a randomized, controlled parallel-group trial. Contemp Clin Trials. 2022;119:106851. doi:10.1016/j.cct.2022.106851
- Ramsden CE, Zamora D, Faurot KR, MacIntosh B, Horowitz M, et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ. 2021;374:n1448. doi:10.1136/bmj.n1448
- Sanders AE, Shaikh SR, Slade GD. Long-chain omega-3 fatty acids and headache in the U.S. population. Prostaglandins Leukot Essent Fatty Acids. 2018;135:47. doi:10.1016/j.plefa.2018.06.008
- Mann JD, Faurot KR, MacIntosh B, Palsson OS, Suchindran CM, et al. A sixteen-week three-armed, randomized, controlled trial investigating clinical and biochemical effects of targeted alterations in dietary linoleic acid and n-3 EPA+DHA in adults with episodic migraine: Study protocol. Prostaglandins Leukot Essent Fatty Acids. 2018;128:41. doi:10.1016/j.plefa.2017.11.002
- Maghsoumi-Norouzabad L, Mansoori A, Abed R, Shishehbor F. Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: A systematic review and meta-analysis of randomized controlled trials. Nutr Neurosci. 2018;21:614. doi:10.1080/1028415X.2017.1344371
- Soares AA, Louçana PMC, Nasi EP, Sousa KMH, Sá OMS, et al. A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline. Nutr Neurosci. 2018;21:219. doi:10.1080/1028415X.2016.1266133
- Sadeghi O, Maghsoudi Z, Khorvash F, Ghiasvand R, Askari G. The relationship between different fatty acids intake and frequency of migraine attacks. Iran J Nurs Midwifery Res. 2015;20:334.
- Ramsden CE, Faurot KR, Zamora D, Suchindran CM, MacIntosh BA, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain. 2013;154:2441. doi:10.1016/j.pain.2013.07.028
- Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21:495.
- Pradalier A, Bakouche P, Baudesson G, Delage A, Cornaille-Lafage G, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia. 2001;21:818.
